Zimmer Biomet Holdings Inc Expected to Earn Q2 2018 Earnings of $1.92 Per Share (ZBH)

Zimmer Biomet Holdings Inc (NYSE:ZBH) – Equities researchers at Jefferies Group lowered their Q2 2018 earnings per share (EPS) estimates for Zimmer Biomet in a research report issued on Thursday. Jefferies Group analyst R. Denhoy now anticipates that the medical equipment provider will post earnings per share of $1.92 for the quarter, down from their prior forecast of $1.95. Jefferies Group currently has a “Buy” rating and a $136.00 target price on the stock. Jefferies Group also issued estimates for Zimmer Biomet’s Q4 2018 earnings at $2.22 EPS.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported $1.72 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.74 by ($0.02). The business had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.83 billion. Zimmer Biomet had a return on equity of 16.29% and a net margin of 8.36%. The firm’s quarterly revenue was down .8% on a year-over-year basis. During the same period last year, the business posted $1.79 earnings per share.

Other research analysts also recently issued reports about the stock. Deutsche Bank raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating and set a $128.00 price objective for the company in a report on Tuesday, November 14th. Edward Jones raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a report on Thursday, November 9th. SunTrust Banks set a $136.00 price objective on shares of Zimmer Biomet and gave the stock a “buy” rating in a report on Wednesday, November 1st. BMO Capital Markets reaffirmed a “buy” rating and issued a $142.00 price objective on shares of Zimmer Biomet in a report on Tuesday, December 12th. Finally, Oppenheimer reaffirmed a “buy” rating on shares of Zimmer Biomet in a report on Tuesday, December 19th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $136.90.

Zimmer Biomet (NYSE ZBH) opened at $120.12 on Friday. The company has a market cap of $24,360.00, a P/E ratio of 37.42, a P/E/G ratio of 1.86 and a beta of 1.15. Zimmer Biomet has a fifty-two week low of $101.43 and a fifty-two week high of $133.49. The company has a quick ratio of 0.78, a current ratio of 1.47 and a debt-to-equity ratio of 0.88.

The company also recently declared a quarterly dividend, which will be paid on Monday, January 29th. Shareholders of record on Friday, December 29th will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.80%. The ex-dividend date is Thursday, December 28th. Zimmer Biomet’s payout ratio is 29.91%.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Ingalls & Snyder LLC lifted its holdings in shares of Zimmer Biomet by 2.6% during the 3rd quarter. Ingalls & Snyder LLC now owns 19,675 shares of the medical equipment provider’s stock worth $2,304,000 after acquiring an additional 507 shares during the last quarter. Private Advisor Group LLC raised its position in Zimmer Biomet by 18.6% in the 3rd quarter. Private Advisor Group LLC now owns 6,733 shares of the medical equipment provider’s stock worth $791,000 after purchasing an additional 1,057 shares during the period. Koch Industries Inc. raised its position in Zimmer Biomet by 49,697.3% in the 2nd quarter. Koch Industries Inc. now owns 1,040,764 shares of the medical equipment provider’s stock worth $1,033,000 after purchasing an additional 1,038,674 shares during the period. Jensen Investment Management Inc. raised its position in Zimmer Biomet by 24.2% in the 2nd quarter. Jensen Investment Management Inc. now owns 5,850 shares of the medical equipment provider’s stock worth $751,000 after purchasing an additional 1,140 shares during the period. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in Zimmer Biomet by 10.0% in the 3rd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 16,444 shares of the medical equipment provider’s stock worth $1,925,000 after purchasing an additional 1,494 shares during the period. 85.92% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This piece was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at https://www.com-unik.info/2017/12/24/zimmer-biomet-holdings-inc-expected-to-earn-q2-2018-earnings-of-1-92-per-share-zbh.html.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Earnings History and Estimates for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit